8 April 2024
08 April 2024 Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours Based on three…
4 April 2024
Chairman’s Statement Dear Shareholder The Merchants Trust was established in 1889, so in 2024 we mark the one hundred and thirty fifth anniversary. We…
2 April 2024
Caledonia Investments plc Transaction in own shares Caledonia Investments plc (“Caledonia”) announces that on 28 March 2024 it purchased from Winterflood Securities Limited 41,459…
As we announced at our Capital Markets Day in November 2023, from Q1 2024 we will be revising our reporting structure to align divisional…
2 April 2024 Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease…
28 March 2024
PERFORMANCE HIGHLIGHTS Total return performance to 31 December One year % Five years % Benchmark1 8.1 31.0 NAV2 9.8 43.6 Share price3 0.9…
James Latham PLC (“James Latham” or the “Company”) Trading Statement The Board of James Latham provides the following trading statement ahead of the Company’s…
JD SPORTS FASHION PLC FY24 TRADING UPDATE OUTPERFORMING A CHALLENGING MARKET JD Sports Fashion Plc (the ‘Group’), the leading retailer of sports, fashion and…